Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Plans Avastin/Tarceva Combo Filing; Avastin Warning Hurts Growth

Executive Summary

Genentech and OSI Pharmaceuticals will be meeting with FDA early in 2005 to discuss filing plans for Tarceva (erlotinib) in pancreatic cancer

You may also be interested in...



Bayer Nexavar Safety Profile Fuels Research In Multiple Cancer Indications

A dual mode of action and favorable safety profile will be the chief selling points for Bayer/Onyx' kidney cancer agent Nexavar (sorafenib), company officials said during Bayer's R&D investor conference in London Dec. 8

Bayer Nexavar Safety Profile Fuels Research In Multiple Cancer Indications

A dual mode of action and favorable safety profile will be the chief selling points for Bayer/Onyx' kidney cancer agent Nexavar (sorafenib), company officials said during Bayer's R&D investor conference in London Dec. 8

Oncologics Will Need Dual Genetic Tests For Optimally Targeted Treatments

The key to successful use of targeted oncologic therapies will be routine genetic testing for both the patient and the tumor, Fox Chase Cancer Center Senior VP Robert Ozols suggested at an American Society of Clinical Oncology briefing Dec. 2

Related Content

Topics

UsernamePublicRestriction

Register

PS045250

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel